Multiple myeloma Cell Models for Research

Multiple myeloma (MM) is a hematologic malignancy characterized by clonal proliferation of plasma cells in the bone marrow. According to the World Health Organization (WHO), MM accounts for approximately 1% of all cancers and 10% of hematologic malignancies. The global incidence was estimated at 160,000 new cases and 106,000 deaths in 2020 (GLOBOCAN). In the United States, the National Cancer Institute (NCI) projects 35,730 new cases and 12,590 deaths in 2023. The 5-year survival rate for localized disease is about 78%, but for distant stage it drops to 60% (SEER). Risk factors include age (median 69), male sex, African ancestry, obesity, and family history. Despite advances with proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies, MM remains incurable, with most patients relapsing or becoming refractory. This underscores the need for better preclinical models to understand resistance mechanisms and develop novel therapies.

MM is an ideal model for studying clonal evolution, tumor microenvironment interactions, and drug resistance. Its genetic heterogeneity, with recurrent mutations in RAS, TP53, and epigenetic regulators, provides a rich landscape for functional genomics. Public datasets such as TCGA (The Cancer Genome Atlas) and the Multiple Myeloma Research Foundation (MMRF) CoMMpass study offer extensive genomic and clinical data. Open questions include the role of specific mutations in disease progression and the development of resistance to targeted therapies. Gene-edited cell models allow researchers to dissect these mechanisms in a controlled in vitro setting, complementing patient-derived xenografts and mouse models.

Multiple myeloma pathogenesis involves several key pathways:

1. NF-κB pathway: Constitutive activation promotes survival and proliferation. Mutations in NF-κB regulators (e.g., TRAF3, CYLD) are common.

2. RAS/MAPK pathway: Activating mutations in KRAS, NRAS, and BRAF drive uncontrolled growth. Present in ~50% of cases.

3. PI3K/AKT/mTOR pathway: Deregulation supports cell survival and drug resistance.

4. JAK/STAT pathway: Interleukin-6 (IL-6) signaling via JAK/STAT is critical for plasma cell growth.

These pathways are interconnected, and their dysregulation contributes to the malignant phenotype.

Data from TCGA and COSMIC.

Key signaling networks in MM include:

• • Wnt/β-catenin: Aberrant activation promotes proliferation and drug resistance.
• • MAPK/ERK: Downstream of RAS, drives cell cycle progression.
• • PI3K/AKT: Supports survival and resistance to apoptosis.
• • JAK/STAT3: Mediates IL-6 growth signals.
• • Notch: Involved in cell-cell communication and drug resistance.

These networks are often activated by genetic alterations or microenvironmental stimuli.

Common MM cell lines include:

Organoids are emerging as 3D models that recapitulate the bone marrow microenvironment, allowing study of cell-cell interactions and drug responses. However, they are less established than cell lines.

Animal models for MM include:

• • Patient-derived xenografts (PDX): Immunodeficient mice engrafted with patient MM cells; preserve tumor heterogeneity.
• • Genetically engineered mouse models (GEMM): Transgenic mice with MM-associated mutations (e.g., MYC, KRAS) under immunoglobulin enhancers.
• • Induced models: Injection of myeloma cell lines into mice (e.g., SCID-hu model) to study tumor growth and metastasis.

These models are valuable for in vivo efficacy testing but are time-consuming and costly.

CRISPR-Cas9 gene editing enables the creation of isogenic cell lines with precise genetic modifications. For MM, common models include:

• • Knockout lines: Inactivation of tumor suppressors (e.g., TP53, FAM46C) to study loss-of-function effects.
• • Knock-in lines: Introduction of oncogenic point mutations (e.g., KRAS G12D, BRAF V600E) to model gain-of-function.
• • Reporter lines: Tagging genes with fluorescent or luminescent markers for live-cell imaging.

These models are sequence-verified and commercially available from various sources, accelerating research by providing consistent, reproducible tools. They are essential for validating drug targets and understanding resistance mechanisms.

Gene-edited cell lines are used to validate the functional role of genes in MM. For example:

• • TP53 knockout lines: Demonstrate loss of tumor suppressor activity, leading to increased proliferation and drug resistance.
• • KRAS knock-in lines: Show activation of downstream signaling pathways and enhanced growth.
• • FAM46C knockout lines: Reveal altered mRNA stability and gene expression.

These models help identify novel therapeutic targets and biomarkers.

Isogenic pairs (wild-type vs. mutant) are used in high-throughput drug screens to identify compounds that selectively kill mutant cells. For instance:

• • KRAS mutant lines: Screened for inhibitors of the MAPK pathway.
• • TP53 mutant lines: Tested for drugs that restore p53 function or induce synthetic lethality.

Resistance models can be generated by chronic drug exposure or by introducing resistance mutations, enabling study of mechanisms and development of second-line therapies.

CRISPR screens using gene-edited cell lines can identify genes whose loss sensitizes cells to specific drugs (synthetic lethality). For example:

• • Screens in TP53-null cells: Identify vulnerabilities that can be targeted therapeutically.
• • Knockout of DNA repair genes: Reveal dependencies on alternative repair pathways.

These approaches lead to the discovery of predictive biomarkers and combination therapies.